{
    "nctId": "NCT05709158",
    "briefTitle": "A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)",
    "officialTitle": "Evaluation of Risk Factors Associated With Myelosuppression (Grade 4 Neutropenia) in Breast Cancer Patients Treated With Palbociclib in the Post-marketing Setting: Nested Case-control Study Using the Medical Information Database Network (MID-NET) Database",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1300,
    "primaryOutcomeMeasure": "Number of Participants With Risk Factors for Grade 4 Neutropenia in Users of Palbociclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Having prescription records of palbociclib from 15 December 2017 to 29 February 2024.\n* Having any breast cancer records in same month as the first prescription date.\n\nExclusion Criteria:\n\n* Having an ANC less than the threshold value for grade 4 neutropenia within 30 days of the first prescription of palbociclib\n* Having any records of anti-HER2 medication",
    "sex": "ALL",
    "minimumAge": "0 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}